Table 5.
Results: subgroup analysis
| Subgroup | Therapeutic Level, n (%) | P | Therapeutic Level on Initial Regimen, n (%) | P |
|---|---|---|---|---|
| Sex | ||||
| Male, (n = 28) | 21 (75.0) | .559 | 9 (32.1) | 1.000 |
| Female, (n = 5) | 5 (100.0) | 2 (40.0) | ||
| Age | ||||
| <35 years, (n = 9) | 5 (55.6) | .068 | 2 (22.2) | .681 |
| ≥35 years, (n = 24) | 21 (87.5) | 9(37.5) | ||
| BMI | ||||
| <30 kg/m2, (n = 20) | 16 (80.0) | 1.000 | 5 (25.0) | .270 |
| ≥30 kg/m2, (n = 13) | 10 (76.9) | 6 (46.2) | ||
| TBSA | ||||
| <20%, (n = 9) | 7 (77.8) | 1.000 | 3 (33.3) | 1.000 |
| ≥20%, (n = 24) | 19 (79.2) | 8 (33.3) | ||
| Time from burn injury to azole initiation | ||||
| ≤3 days, (n = 7) | 7 (100.0) | .299 | 3 (42.9) | .661 |
| ≥3 days, (n = 26) | 19 (73.1) | 8 (30.8) | ||
| Azole agent | ||||
| Voriconazole, (n = 21) | 17 (81.0) | .686 | 10 (47.6) | .027 |
| Posaconazole, (n = 12) | 9 (75.0) | 1 (8.3) | ||
| Loading dose administered | ||||
| Yes, (n = 21) | 16 (76.2) | 1.000 | 5 (23.8) | .149 |
| No, (n = 12) | 10 (83.3) | 6 (50.0) | ||
| Azole formulation for the first regimen | ||||
| IV, (n = 13) | 11 (84.6) | .850 | 3 (23.1) | .108 |
| PO tablets, (n = 16) | 12 (75.0) | 8 (50.0) | ||
| PO suspension, (n = 4) | 3 (75.0) | 0 (0.0) | ||
| Concurrent acid-suppressive therapy* | ||||
| Yes, (n = 1) | 1 (100.0) | 1.000 | 0 (0.0) | — |
| No, (n = 3) | 2 (66.7) | 0 (0.0) | ||
| Concurrent enteral feeding† | ||||
| Yes, (n = 18) | 14 (77.8) | .502 | 8 (44.4) | .338 |
| No, (n = 2) | 1 (50.0) | 0 (0.0) |
*Includes only patients treated with posaconazole via the PO (by mouth), NG (nasogastric), NJ (nasojejunal) routes.
†Includes only patients treated with azole therapy via the PO (by mouth), NG (nasogastric), NJ (nasojejunal) routes. Excludes those with clear documentation of enteral feeds being held prior to azole administration.